Afecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators

Patent ExpiryNeuro-Immuno ModulatorsPositive

AI Analysis

Summary

Afecta Pharmaceuticals has been granted a new US patent (No. 12,673,957) for 'Inhibition of Glial Cell Activation,' covering its neuro-immuno modulators being developed for complex disorders.

Outcome Details

USPTO granted new patent US Patent No. 12,673,957 for 'Inhibition of Glial Cell Activation'

Importance:3/10

Sentiment:

0.50

patentintellectual propertyneuro-immuno modulatorsglial cell activationUSPTO

Related Companies

$CBDY

Read the original article

Published by PR Newswire Biotech on August 25, 2026 1:22 PM

Read Original